|Daily Range||$36.29 - $36.54|
|52-Week Range||$30.91 - $38.71|
|Dividend (Yield)||$0.00 (2.5%)|
|Average Daily Volume||589,797|
|Current FY EPS||$2.06|
Exelixis stock takes one on the chin after the company's lead compound fails to provide a statistically significant survival benefit in a late stage prostate cancer trial. Find out what's next for this highly-followed biotech stock.
Roche stuns Wall Street and investors by snatching up InterMune and its first-in-class lung disease drug. But, does this deal make sense?
Roche continues to build upon the strongest oncology franchise in Big Pharma but could still use some non-oncology hits
The company's tablet, Zydelig, works by blocking signals inside some cancer cells that allow them to grow and survive.
Pfizer gives Puma Biotechnology a gift, while Puma might be able to steal sales from Roche.
Exelixis has a great lineup of promising oncology candidates, but will it be able to develop them?
A successful phase 3 study has started rumors that Roche may bid for Exelixis
Good news from Exelixis' partner Roche, but we don't know if the trial data is good enough to beat GlaxoSmithKline's competing regimen.
Roche is about to release phase 2 data that could redefine its opportunity in this extremely hard-to-treat disease
Johnson & Johnson, Roche, Novartis, Google are the top stocks to watch in health care this Tuesday morning.